Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • ROOMS:

GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

Collaboration expected to accelerate identification of patients with an elevated risk for cancer

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Premier, Inc.’s PINC AI™, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test.

Under the partnership, Premier’s PINC AI will augment its AI-enabled clinical decision support technology to alert clinicians to patients who present an elevated risk of cancer and may benefit from early detection with the Galleri test. The alert will be evidence-based, integrated in the workflow and is expected to be compatible with existing electronic medical record systems. Indianapolis-based Community Health Network is expected to be the first health system to pilot candidate alerts.

“At GRAIL, we are steadfast in our mission to detect cancer early. We are committed to making Galleri available to healthcare providers and eligible patients as a complement to guideline recommended cancer screenings, because we know that most cancers are diagnosed too late, when outcomes are poor,” said Dr. Joshua Ofman, president and chief medical officer at GRAIL. “The partnership with Premier’s PINC AI, a trusted leader in healthcare technology, will support a key pillar of new early cancer detection technology – the identification of eligible patients through healthcare providers’ existing workflows.”

“PINC AI augments clinical intelligence and helps ensure patients receive evidence-based care,” said Leigh Anderson, president of Premier’s PINC AI. “Our goal with the new candidate alerts is to ensure more patients who need a cancer screening get one. We believe that Galleri is a game-changing screening tool that has the potential to increase early detection and treatment that can save lives, improve quality and reduce unnecessary costs.”

More than 600,000 people die from cancer each year in the U.S., according to the American Cancer Society. This is in large part because the majority of cancers are found in later stages when treatment options are limited. Recommended screening tests only cover five cancer types in the U.S.: breast, colon, cervical, prostate, and, in high-risk smokers, lung. More than 70 percent of cancer deaths are from cancers that lack recommended early detection screening.

In addition, studies have demonstrated that stage at diagnosis has the greatest impact on costs, with decreased costs for patients diagnosed early in the disease compared to those diagnosed at later stages.

“Galleri is a validated and transformational test that can detect more than 50 cancers with a single blood draw and predict the origin with a high degree of accuracy and a low rate of false positives,” said Patrick McGill, M.D., executive vice president and chief transformation officer at Community Health Network. “With this collaboration between PINC AI and GRAIL, our clinicians will be alerted when patients meet certain criteria for the ordering of a Galleri test. We believe this will make Community Health Network much more effective in our efforts to detect cancers early, when treatments are more effective, giving our patients the best chances of a successful outcome. Thanks to Community Health Network’s Foundation sponsorship and funding, we are proud to be the first health system taking advantage of this collaboration.”

Galleri is available in the U.S. by prescription only to complement existing single cancer screening tests.

About Galleri

The earlier that cancer is detected, the higher the chance of successful outcomes. The Galleri multi-cancer early detection test can detect more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or where the cancer is located in the body, with high accuracy to help guide the next steps to diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people with an elevated risk of cancer, such as those aged 50 or older.

For more information about Galleri, visit


GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a wholly-owned subsidiary of Illumina, Inc. (NASDAQ:ILMN). For more information, please visit


PINC AI™ is the technology and services platform of Premier Inc. (NASDAQ: PINC). Made up of 20 years’ worth of cost, quality and operational data gleaned from over 45 percent of U.S. hospital discharges annually, as well as 812 million hospital outpatient and clinic encounters and 131 million physician office visits, PINC AI provides actionable intelligence that helps improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI offerings rely on advanced analytics to identify improvement opportunities, consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. PINC AI is also the data engine powering Premier’s newest brands – Remitra™ and Contigo Health®. With a leading network of provider organizations, PINC AI accelerates ingenuity and serves as a large-scale innovation catalyst in healthcare. Premier, Inc, is headquartered in Charlotte, N.C.. PINC AI can be followed on Twitter and LinkedIn.

Important Galleri Safety Information

Galleri is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Galleri is prescription only.

Laboratory/Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has been approved by New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP). The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Photography by Christophe Tomatis
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.